Can Artiva Biotherapeutics, Inc. turn deep B-cell depletion into a scalable autoimmune treatment model?
Can AlloNK make autoimmune cell therapy scalable? Explore why Artiva Biotherapeutics, Inc.’s rheumatoid arthritis strategy matters.
Why 10x Genomics is betting on peripheral blood to decode complex immune disorders
Find out how 10x Genomics and Brigham & Women’s Hospital are using single-cell profiling to redefine autoimmune diagnostics. Can it change patient care?
Will Surf’s SUSTAIN platform bring at-home neuromodulation to mainstream rheumatology?
Surf begins human trial for ultrasound-based neuromodulation in RA. Can it challenge biologics? Find out what this means for autoimmune therapy access.
Can Gotenfia finally unlock biosimilar competition for Simponi in Europe?
STADA Arzneimittel AG and Bio-Thera Solutions have secured a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for Gotenfia, a proposed biosimilar to the tumor necrosis factor alpha inhibitor golimumab. The product references Simponi, an originator drug widely prescribed for multiple autoimmune conditions. If approved, Gotenfia would be marketed […]